Protagonist Therapeutics Inc PTGX
News
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda